Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Portfolio Pulse from Vandana Singh
Athira Pharma's Alzheimer's drug candidate, fosgonimeton, failed to show significant improvement in cognition and function in a Phase 2/3 trial, leading to a 72.8% drop in ATHA stock. The trial's results were not statistically significant, although some directional improvements were noted in certain subgroups.
September 04, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Athira Pharma's Alzheimer's drug candidate, fosgonimeton, did not achieve statistically significant results in improving cognition and function in a Phase 2/3 trial. This led to a significant drop in ATHA stock price by 72.8%.
The failure of fosgonimeton to show statistically significant improvement in the trial is a major setback for Athira Pharma, directly impacting investor confidence and causing a sharp decline in stock price. The lack of significant results in the primary endpoints and the substantial stock price drop highlight the critical nature of this news for investors.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100